For triple-negative breast cancer (TNBC), four ongoing clinical trials are evaluating FDA-approved CDK4/6 inhibitors as monotherapies (NCT03979508) in combination with anti-androgen receptor (AR) therapy in AR-positive (AR+) populations (NCT02605486 and NCT03090165) or with a histone deacetylase (HDAC) inhibitor (NCT04315233). Here, AR is linked to triple-negative breast carcinoma.